 |
|
|
|
|
VOLUME 2, ISSUE 8
|
Ovarian Cancer
The table below summarizes the available evidence on the risks and benefits of hormone therapy. Included
are all randomized trials and meta-analyses looking at disease incidence or mortality. Inclusion of observational trials was dependent on size:
case-control studies with 500 or more cases of the disease and cohort studies with at least 2,000 women
are included here.
The year noted is when the study results were published. The name following the title of the study is the last
name of the first author on the publication.
E = estrogen; P = progestin
|
Year
|
Study
|
Study Type
|
Participants
|
Hormones
|
Results
|
Other Notes
|
|
1992
|
Whittemore
|
Meta-analysis
|
12 studies
|
E, E + P
|
No increased risk
|
No distinction between E vs. E+P
|
|
1995
|
Purdie
|
Case-control
|
824 cases,
860 controls
|
E, E+P
|
No increased risk
|
No distinction between E vs. E+P
|
|
1998
|
Garg
|
Meta-analysis
|
17 studies
|
E, E+P
|
Ever-use increased risk 15%; > 10 years
of use increased risk 27%
|
No distinction between E vs. E+ P
|
|
1999
|
Negri
|
Meta-analysis
|
4 case-control studies
|
E, E+P
|
70% increased risk
|
No distinction between E vs. E+P
|
|
2000
|
Coughlin
|
Meta-analysis
|
15 case-control studies
|
E
|
No association
|
No clear evidence of dose response
|
|
2001
|
Rodriguez
|
Cohort
|
211,581
|
E
|
Increases mortality 100% with 10 or more
years of use
|
Women reported use through 1982; followed for 14 years
|
|
2002
|
Riman
|
Case-control
|
655 cases, 3,899 controls
|
E, E + P
|
E alone and E with 10 days/month P
increase risk about 50%
|
No increase in risk with continuous P
use
|
|
2002
|
Lacey
|
Cohort
|
44,241
|
E, E + P
|
E alone increases risk
60%; risk increases with duration of use
|
20 years follow-up; with & without
uterus; not enough data for E + P
|
|
|
|
|
|
Animation/Video
Audio Clips
Photos/Stills
